Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
- PMID: 33637203
- DOI: 10.1016/j.kint.2020.10.026
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Abstract
The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorous process of evidence review and appraisal. Guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence. The strength of recommendations is based on the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. The scope includes topics covered in the original guideline, such as optimal blood pressure targets, lifestyle interventions, antihypertensive medications, and specific management in kidney transplant recipients and children. Some aspects of general and cardiovascular health, such as lipid and smoking management, are excluded. This guideline also introduces a chapter dedicated to proper blood pressure measurement since all large randomized trials targeting blood pressure with pivotal outcomes used standardized preparation and measurement protocols adhered to by patients and clinicians. Based on previous and new evidence, in particular the Systolic Blood Pressure Intervention Trial (SPRINT) results, we propose a systolic blood pressure target of less than 120 mm Hg using standardized office reading for most people with chronic kidney disease (CKD) not receiving dialysis, the exception being children and kidney transplant recipients. The goal of this guideline is to provide clinicians and patients a useful resource with actionable recommendations supplemented with practice points. The burden of the recommendations on patients and resources, public policy implications, and limitations of the evidence are taken into consideration. Lastly, knowledge gaps and recommendations for future research are provided.
Keywords: KDIGO; albuminuria; ambulatory blood pressure monitoring; angiotensin II receptor blocker; angiotensin-converting enzyme inhibitor; antihypertensive agents; automated office blood pressure; blood pressure measurement; blood pressure targets; children; chronic kidney disease; creatinine; diabetes; dietary sodium; evidence-based; guideline; home blood pressure monitoring; hyperkalemia; kidney transplant recipient; lifestyle; mineralocorticoid receptor antagonist; office blood pressure; physical activity; potassium; proteinuria; renin-angiotensin system; standardized office blood pressure; systematic review; weight loss.
Copyright © 2021 KDIGO. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD.Curr Cardiol Rep. 2021 Aug 16;23(9):132. doi: 10.1007/s11886-021-01559-3. Curr Cardiol Rep. 2021. PMID: 34398316 Free PMC article. Review.
-
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.Kidney Int. 2022 Nov;102(5):990-999. doi: 10.1016/j.kint.2022.06.013. Kidney Int. 2022. PMID: 36272755
-
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.Kidney Int. 2024 Apr;105(4):684-701. doi: 10.1016/j.kint.2023.10.016. Kidney Int. 2024. PMID: 38519239
-
Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States.Kidney Int. 2021 Mar;99(3):686-695. doi: 10.1016/j.kint.2020.12.019. Kidney Int. 2021. PMID: 33637204 Free PMC article.
-
Commentary on the 2021 update of the KDIGO clinical practice guideline for management of blood pressure in chronic kidney disease.Nephrology (Carlton). 2025 Jan;30(1):e14414. doi: 10.1111/nep.14414. Nephrology (Carlton). 2025. PMID: 39725407 Review.
Cited by
-
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.Nat Rev Nephrol. 2022 Nov;18(11):696-707. doi: 10.1038/s41581-022-00616-6. Epub 2022 Sep 14. Nat Rev Nephrol. 2022. PMID: 36104509 Review.
-
The Complex Immunological Alterations in Patients with Type 2 Diabetes Mellitus on Hemodialysis.J Clin Med. 2024 Jun 25;13(13):3687. doi: 10.3390/jcm13133687. J Clin Med. 2024. PMID: 38999253 Free PMC article. Review.
-
[Cardiovascular treatment in chronic kidney disease].Herz. 2023 Oct;48(5):413-424. doi: 10.1007/s00059-023-05205-2. Epub 2023 Sep 11. Herz. 2023. PMID: 37695534 Review. German.
-
New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy.High Blood Press Cardiovasc Prev. 2022 Mar;29(2):125-135. doi: 10.1007/s40292-021-00495-1. Epub 2021 Dec 15. High Blood Press Cardiovasc Prev. 2022. PMID: 34910287 Free PMC article. Review.
-
Tissue Sodium Accumulation Induces Organ Inflammation and Injury in Chronic Kidney Disease.Int J Mol Sci. 2023 May 5;24(9):8329. doi: 10.3390/ijms24098329. Int J Mol Sci. 2023. PMID: 37176037 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical